New drug combo aims to fight spread of prostate cancer
NCT ID NCT07140900
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking at how well the combination controls the cancer. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xaluritamig (a type of immunotherapy) combined with darolutamide or abiraterone (hormone-blocking drugs)
What this could lead to
If it works, this could lead to a more effective treatment option for men with metastatic hormone-sensitive prostate cancer.
What could go wrong
This is an early Phase 1b trial with only 60 participants, focused on safety. It is too soon to know if the combination will be effective or have manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cabrini Hospital
RECRUITINGClayton, Victoria, 3168, Australia
-
Calvary Mater Newcastle Hospital
RECRUITINGWaratah, New South Wales, 2298, Australia
-
Centre Hospitalier Universitaire Vaudois
RECRUITINGLausanne, 1011, Switzerland
-
Chris OBrien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Kantonsspital Graubuenden
RECRUITINGChur, 7000, Switzerland
-
Kantonsspital Sankt Gallen
RECRUITINGSankt Gallen, 9007, Switzerland
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics - Carolinas
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94158, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States